In Vivo Evaluation of Nav1.7 Inhibiting ProTx-II Analogs
Greg Adams
Associate Director Discovery Chemistry • Drug Design, Former Merck & Co. / Currently at Exscientia
Merck is a premier research-intensive biopharmaceutical company
Exscientia is a pharamtech company that applies artificial intelligence to rapidly and efficiently precision engineer medicines
Greg has nearly 20 years of experience working as a discovery chemist across multiple modalities. Previous companies include Merck and GSK. He is currently working at Exscientia, leading chemistry efforts while utilizing artificial intelligence to enable design.